Form 4: Kura Oncology COO Kathleen Ford Reports Stock Purchase Under 10b5-1 Plan

Kathleen Ford, COO of Kura Oncology, reports the purchase of 1,558 shares of common stock at an average price of $6.2756, executed under a pre-arranged 10b5-1 trading plan.

Summary

• Kathleen Ford, the Chief Operating Officer of Kura Oncology, reported a transaction involving the company's common stock.
• On May 19, 2025, Ford acquired 1,558 shares of common stock.
• The shares were purchased at a weighted average price of $6.2756.
• The transaction was executed under a Rule 10b5-1 trading plan adopted on June 10, 2024.
• Following the reported transaction, Ford directly owns 21,367 shares of Kura Oncology stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The purchase of shares by an executive is generally a good sign, but the transaction was pre-planned and relatively small.

Positives

• The purchase of shares by a company executive can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure of insider trading activity. It is common for executives to set up 10b5-1 trading plans to avoid accusations of trading on inside information. The purchase is relatively small and may not have a significant impact on the stock price.

Comparison to Industry Standards

• Insider trading activity is closely monitored in the pharmaceutical industry, similar to other sectors.
• Companies like Amgen, Gilead, and Biogen also have executives who regularly trade shares under 10b5-1 plans.
• The size and frequency of these trades are generally comparable across companies of similar market capitalization.

Stakeholder Impact

• The stock purchase could have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Kura Oncology, Kathleen Ford, Form 4, Stock Purchase, Rule 10b5-1, Insider Trading, COO, KURA